Filtered By:
Source: European Review for Medical and Pharmacological Sciences
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 2216 results found since Jan 2013.
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research
Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5636-5653. doi: 10.26355/eurrev_202306_32804.ABSTRACTNeurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder associated with an increased risk of developing a variety of benign and malignant tumors. Fifteen to 20% of children with NF1 are diagnosed with an optic pathway glioma (NF1-OPG) before 7 years of age, and more than half of them experience visual decline. At present, no effective therapy is available for prevention, restoration, or even stabilization of vision loss in subjects affected by NF1-OPG. This paper aims to review the main emerging pharmacological ...
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: A Amato B P Imbimbo B Falsini Source Type: research
Efficacy of traditional herbal formulas on human immunity
Eur Rev Med Pharmacol Sci. 2023 Jun;27(4 Suppl):27-40. doi: 10.26355/eurrev_202306_32743.ABSTRACTIn the present study, we reviewed the efficacy of traditional herbal formulas on human immunity. A literature survey was performed in PubMed, UpToDate, Proquest Central Databases of Kırıkkale University, Google and Google Scholar databases from the internet. Search key words were "immune", "immune system", "herbal", "Pelargonium Sidoides", "Echinacea Purpurea", "Sambucus Nigra", "Beta Glucan", "Vitamin C", "Zinc". The immune system is a natural self-defense mechanism made up of cells that assist the body in distinguishing bet...
Source: European Review for Medical and Pharmacological Sciences - June 23, 2023 Category: Drugs & Pharmacology Authors: C Cingi N Bayar Muluk A Tezol I Çukurova Source Type: research
